Pros and Cons of Telemedicine for Inherited Metabolic Disorders in a Developing Country During the COVID-19 Pandemic


Introduction

The COVID-19 pandemic has affected the whole world, and it has led to many changes in society, the economy, and the health care system. Experts recommend that individuals isolate themselves at home as much as possible.1 Telemedicine systems have come to play a crucial role in reducing human contact when accessing health services.2,3

Telemedicine has witnessed an unprecedented upward trend since the announcement of the pandemic.4,5 In addition, with the announcement of curfews by governments, it has been recommended that health services be accessed from home all over the world.6 People have become more familiar with technology and Internet applications as a result of the pandemic, and this has been reflected positively in telemedicine applications.5

Individuals with chronic conditions who rely on continuous health care faced difficulties in accessing health care during the pandemic.7 Inherited metabolic disorders (IMDs), which fall into this group, require regular follow-up if a clinical worsening of the condition is to be avoided. Disruptions in the follow-up and treatment of patients with IMDs can lead to cognitive impairment, coma, and even death, and so such patients need to be in regular communication with their doctors. Telemedicine has emerged as a potential solution to the problem of health care access for patients with IMDs in the ongoing COVID-19 pandemic.8

Since many developing countries lack sufficient telemedicine infrastructure, it is crucial to identify the components that determine patient–parent satisfaction to improve the provision of health care services.9,10 Accordingly, the needs of patients with IMDs, the parents’ expectations, and the limitations of families are required to be understood.9–12

Telemedicine is not a routine application of the health system in Turkey. As in the whole world, interest in telemedicine has increased in Turkey during the COVID-19 pandemic. Studies on telemedicine usability and patients’ satisfaction in Turkey show that telemedicine is highly needed in daily practice in our country. It can be a safe and low-cost alternative to eliminate the grievances of chronic pediatric patients in our country.13

In the present study, we evaluate the effectiveness of telemedicine for those with IMDs during the COVID-19 pandemic.

Methods

PATIENT COHORT AND DATA EXTRACTION

This prospective study was conducted by making use of a new video appointment program, designed by the Department of Computer Engineering, Ankara University Engineering Faculty with the privacy and confidentiality of the patients and parents in mind. The program allowed video appointments to be conducted by involving the patient and the doctor.

An account was created by the doctors, and appointment dates were set for the patients who agreed to participate. Information on how to connect to the system was provided to the patients/parents by the doctors by phone. At the date and time of the appointment, each patient entered their unique ID number and password. The doctors offered guidance when the parents encountered problems.

The parents of 212 of the patients being followed up by the Pediatric Metabolism Department were called by phone and invited to take part in a video appointment, among whom 11 declined to participate due to their unfamiliarity with the system, their concerns over safety, and their inability to spare the time for an appointment. Of the total, 174 of the parents (86.5%) were able to successfully connect to the system and took part in a video appointment. Of the remainder, 13 parents reported that they could not attend due to Internet problems and 14 parents had computer/mobile phone problems (Fig. 1). The consent of those who were able to connect successfully to the system and who participated was obtained electronically through the system.

Fig. 1.

Fig. 1. Study flow chart.

Before the video appointments, the clinical files of the patient were evaluated by the doctor, who discussed the patients’ complaints, medications, diet, and last laboratory results with the family during the appointments. Any clinically stable patients who reported acute complaints were referred to the pediatric emergency department by the doctor. At the end of the video appointments, the sociodemographic characteristics of the patients, their clinical situations, their views on the telemedicine system, and their satisfaction levels were questioned. Participants filled out the questionnaires themselves through the technological interface online, and they recorded them before exiting the system.

Approval for the development and use of the program was obtained from the Ankara University Ethics Committee, and it was made ready for use through trial appointments (Ethics committee code i5-270-20). The research was conducted under the ethical and humane principles of the study established by the Declaration of Helsinki.

STATISTICAL ANALYSIS

Data were recorded with IBM SPSS Statistics for Macintosh (Version 27.0; IBM Corp., Armonk, NY). Continuous variables were presented as median (25th–75th percentiles) or mean with standard deviation, whereas categorical variables were presented as percentages.

Results

SOCIODEMOGRAPHIC CHARACTERISTICS

Overall, 174 patients were included in the study, among whom 84 (48.3%) were female and 90 (51.7%) were male. The median age of the patients was 6.3 years (25th–75th percentile: 3.0–10.7). The median age of the parents participating in the appointment was 36 years (25th–75th percentile: 31–40). The participants reported their education levels as 33.3% high school, 20.7% middle school, and 18.4% elementary school. Of the parents, 104 (59.8%) said that they were unemployed (Table 1), 27 reported an income less than 210.00 United States Dollars (USD) (hunger threshold), 152 parents reported an income less than 625.00 USD (poverty threshold), and 10 reported no income.

Table 1. Sociodemographic Characteristics

FEATURES
Gender, n (%)
 Female 84 (48.3)
 Male 90 (51.7)
Age of patients, median-years [25th–75th percentile] 6.3 [3.0–10.7]
Interviewees, n (%)
 Mother 95 (54.6)
 Father 22 (12.6)
 Mother and father together 7 (4)
 Patient with parents 50 (28.7)
Age of interviewees, median-years [25th–75th percentile] 36 [31–40]
Education status of interviewee, n (%)
 No formal education 3 (1.7)
 Elementary school 32 (18.4)
 Middle school 36 (20.7)
 High school 58 (33.3)
 University 28 (16.1)
 Master/doctorate 17 (9.8)
Occupational status of interviewee, n (%)
 Working 70 (40.2)
 Not working 104 (59.8)
Income, n (%)
 None 10 (5.7)
 <210 USD (hunger threshold) 27 (15.5)
 210–415 USD 79 (45.4)
 415–625 USD (poverty threshold) 36 (20.7)
 >625 USD 22 (12.6)
Persons per house, median [25th–75th percentile] 4 [4–5]
Number of siblings, median [25th–75th percentile] 1 [0–2]
Education status of patients, n (%)
 None, too young 81 (46.6)
 Formal education 64 (36.8)
 Special education 11 (6.3)
 Formal and special education 18 (10.3)
Distance from residence to metabolic unit (km), n (%)
 <300 109 (62.6)
 300–500 39 (22.4)
 500–1,000 15 (8.6)
 >1,000 11 (6.3)
Time taken to get to the metabolism unit, n (%)
 <30 min 47 (27.0)
 30 min–1 h 42 (24.1)
 1–3 h 24 (13.7)
 3–6 h 38 (21.8)
 6–12 h 11 (6.3)
 >12 h 12 (6.8)
Travel, n (%)
 Walking 6 (3.4)
 Public transport (bus, train) 50 (28.7)
 Private/taxi 112 (64.3)
 Air travel 6 (3.4)
Number of public transport vehicles used in Ankara (n = 35), n (%)
 1 18 (51.4)
 2 and more 17 (48.6)
Travel cost to metabolism unit, n (%)
 0 USD (pedestrian) 6 (3.4)
 1–10 USD 91 (52.2)
 10–50 USD 29 (16.6)
 50–100 USD 16 (9.2)
 100–125 USD 14 (8.0)
 125–250 USD 16 (9.2)
 >250 USD 2 (1.1)
Accommodation (for those from outside Ankara, n = 65), n (%)
 Hotel/pension 43 (66.1)
 Friends’ house/relatives’ house 22 (33.8)
Accommodation expenses (for those from outside Ankara, n = 65), n (%)
 <50 USD 26 (40)
 50–100 USD 14 (21.5)
 100–125 USD 16 (24.6)
 125–175 USD 7 (10.7)
 >175 USD 2 (3)
Difficulty finding accommodation (for those from outside Ankara, n = 65), n (%)
 Yes, always 37 (56.9)
 Sometimes 7 (10.7)
 No 21 (32.3)
Absence from work to go to the hospital (for interviewee or other parent), n (%)
 Yes 119 (68.4)
 No 55 (31.6)
Difficulty getting time off work (n = 119), n (%)
 Sometimes 41 (34.4)
 Yes 42 (35.2)
 No 36 (30.2)
Regular attendance to the outpatient clinic, n (%)
 Yes 106 (60.9)
 No 68 (39.1)
Reasons for not coming regularly to the outpatient clinic (n = 68), n (%)
 Travel issues 34 (50)
 COVID-19 anxiety 31 (45.6)
 Financial issues 26 (38.1)
 Not being able to take time off work 12 (17.6)
 Having other individuals to be cared for at home 10 (14.7)
 Accommodation issues 8 (11.8)
 Forgetting the appointment 7 (10.3)

Of the total, 109 of the participants (62.6%) lived in Ankara, where the hospital is located. Of those, 68 (62.3%) reported arriving at the hospital by private car/taxi and 35 (32%) by public transport; 62 (56.8%) reported taking more than 30 min to get to the hospital. Of the 65 participants living outside Ankara, 61 (93.8%) reported that their journey had taken longer than 3 h; 49.2% reported travel expenses amounting to 100.00 USD or more, Of them, 43 (66.1%) reported staying at a hotel/pension, and 22 (33.8%) at a friends’ or relatives’ house; 39 (60%) reported spending 50.00 USD or more on accommodation; and 44 (67.9%) stated that they had difficulty in finding accommodation. The mothers or fathers of 119 patients said that they had taken time off work to go to the hospital, among whom 83 (69.6%) stated that they had difficulty in taking time off work. Further, of the 68 who could not attend the regular outpatient clinic controls, 50 percent gave the reason as travel issues, 45.6% COVID-19 anxiety, and 38.1% financial issues (Table 1).

CLINICAL FEATURES

Of the 174 patients included in the study, aminoacidopathies were the most common disorders (24.7%), followed by lipid metabolism disorders, biotinidase deficiency, and lysosomal/peroxisomal diseases, with rates of 21.8%, 19.5%, and 7.5%, respectively (Table 2).

Table 2. Clinical Features of Patients

FEATURES
Diagnosis, n (%)
 Aminoacidopathies 43 (24.7)
 Lipid metabolism disorders 38 (21.8)
 Biotinidase deficiency 34 (19.5)
 Lysosomal/peroxisomal diseases 13 (7.5)
 Mitochondrial diseases 11 (6.3)
 Organic acidemias 10 (5.7)
 Carbohydrate metabolism disorders 8 (4.6)
 Congenital disorders of glycosylation 4 (2.3)
 Urea cycle disorders 4 (2.3)
 Fatty acid oxidation disorders 2 (1.1)
 Purine and pyrimidine metabolism disorders 1 (0.6)
 Others 6 (3.4)
Years of follow-up, median [25th–75th percentile] 3 1.5–5.1
Treatments, n (%)
 None 23 (13.2)
 Oral medication 126 (72.4)
 Enzyme replacement therapy at hospital 7 (4)
 Diet 82 (47.1)
Frequency of doctor follow-up (months), n (%)
 <3 43 (24.7)
 3–6 101 (58)
 6–12 19 (10.9)
 >12 11 (6.3)
Frequency of laboratory tests (months), n (%)
 <3 39 (22.4)
 3–6 104 (59.8)
 6–12 20 (11.5)
 >12 11 (6.3)
Frequency of dietitian follow-up (months), n (%)
 None 92 (52.9)
 <3 25 (14.4)
 3–6 34 (19.5)
 6–12 14 (8)
 >12 9 (5.2)
Frequency of prescription/health report (months), n (%)
 None 28 (16.1)
 <3 34 (19.5)
 3–6 74 (42.5)
 6–12 25 (14.4)
 >12 13 (7.5)
Waiting time for examination in the waiting room of the outpatient clinic (minutes), n (%)
 <15 25 (14.4)
 15–30 76 (43.7)
 30–45 52 (29.9)
 >45 21 (12.1)
Motivation problems related to medication and diet when unable to come to the outpatient clinic follow-up (for patients taking treatment n = 151), n (%)
 Yes 73 (48.3)
 No 78 (51.7)

The participants reported being followed by the pediatric metabolism department for an average of 3 years (25th–75th percentile: 1.5–5.1), 126 (72.4%) reported receiving oral medication, 82 (47.1%) underwent diet therapy, and seven (4%) received enzyme replacement therapy (ERT) at the hospital. Of the total, 144 participants (82.7%) said they came to the hospital for doctor’s follow-up, 82.2% for laboratory tests, 33.9% for dietitian follow-up, and 62% for prescription/health reports at less than 6-month intervals. Further, 73 (48.3%) of the 151 participants who received treatment reported motivation problems related to the treatment as the reason for not regularly attending the outpatient clinic controls (Table 2).

FEATURES OF VIDEO APPOINTMENTS

During the telemedicine, 137 of the participants (78.7%) used mobile phones, and 116 participants (66.7%) used their home Wi-Fi. When asked about the specific advantages of telemedicine, the most common response was time saving (93.1%), followed by journey elimination (86.8%) and elimination of travel expenses (81.6%). The most commonly reported disadvantages were the lack of access to radiological and laboratory tests (83.9%), and the lack of any physical examination (70.7%).

The participants stated that in the future they could use telemedicine to learn radiological and laboratory results (94.8%), to obtain prescription/health reports (76.4%) and to reach the doctor in case of an emergency (62.6%). Of the total, 170 (97.7%) participants stated that they found telemedicine to be useful, three were not entirely sure about the benefit, 168 (96.6%) said that they would prefer telemedicine in the future, and 157 found it more convenient to meet via video (Table 3).

Table 3. Patients’ Answers to Questions About Telemedicine

QUESTIONS n (%)
Which device did you use to connect to the telemedicine service?
 Mobile phone 137 (78.7)
 Laptop 23 (13.2)
 Desktop computer 7 (4)
 Tablet computer 7 (4)
Which Internet network did you use?
 Home Wi-Fi 116 (66.7)
 Mobile phone Internet 52 (29.9)
 Wi-Fi of friend/relative 4 (2.3)
 Other 2 (1.1)
Duration of telemedicine interview (minutes)
 <15 67 (38.5)
 15–30 87 (50)
 30–45 18 (10.3)
 >45 2 (1.1)
What are the advantages of telemedicine?
 Time savings 162 (93.1)
 Journey savings 151 (86.8)
 Travel expenses savings 142 (81.6)
 Not having to come to hospital 140 (80.5)
 A solution to taking time off work 82 (47.1)
 Motivation for drugs and diet 62 (35.6)
 A solution to taking time off school 16 (9.2)
What are the disadvantages of telemedicine?
 No access to radiological and laboratory tests 146 (83.9)
 No access to physical examination 123 (70.7)
 Not prescribing treatment 81 (46.6)
 Not keeping medical records 52 (29.9)
In which areas would you like to use telemedicine in the future?
 Results of radiological and laboratory tests 165 (94.8)
 Prescription/health reports 133 (76.4)
 For urgent consultations with the doctor 109 (62.6)
 Doctor routine follow-up 89 (51.1)
 Dietitian follow-up 64 (36.8)
Did you find telemedicine useful?
 Yes 170 (97.7)
 No 1 (0.6)
 I am not sure 3 (1.7)
Would you prefer telemedicine in the future?
 Yes 168 (96.6)
 No 0 (0)
 I am not sure 6 (3.4)
Which method would you prefer for telemedicine?
 Video call 157 (90.2)
 Voice call 17 (9.8)

TELEMEDICINE SATISFACTION ASSESSMENT

The participants were questioned about their satisfaction with the telemedicine system from two perspectives, being its technical and health services aspects, scoring each response in a range from 1: very bad to 5: very good. The scores of each question are presented in sub-headings. The mean telemedicine satisfaction point given by parents in terms of technical and health care was 94.6 ± 10.1 out of 100. Satisfaction survey questions and the answers are presented in Table 4.

Table 4. Satisfaction Survey Questions

QUESTIONS n (%)
1 2 3 4 5
A. Telemedicine technical satisfaction
 A1. How easy was it to connect to the system? 1 (0.6) 5 (2.9) 19 (10.9) 47 (27) 102 (58.6)
 A2. How easy was it to connect to the system without having to ask for help? 2 (1.1) 12 (6.9) 26 (14.9) 51 (29.3) 83 (47.7)
 A3. How would you rate the response of the telemedicine team to questions about the system? 0 (0) 4 (2.3) 7 (4) 14 (8) 149 (85.6)
 A4. How was the sound quality of the telemedicine system? 5 (2.9) 11 (6.3) 26 (14.9) 30 (17.2) 102 (58.6)
 A5. How was the clarity of your doctor’s voice? 6 (3.4) 4 (2.3) 25 (14.4) 23 (13.2) 116 (66.7)
 A6. How well did your doctor hear your conversations? (in your opinion) 7 (4) 2 (1.1) 10 (9.2) 23 (13.2) 126 (72.4)
 A7. How was the visual quality of the telemedicine system? 9 (5.2) 4 (2.3) 12 (6.9) 37 (21.3) 112 (64.4)
 A8. How was the screen flow of the telemedicine system? (pauses and screen freezes) 8 (4.6) 5 (2.9) 21 (12.1) 35 (20.1) 105 (60.3)
 A9. How was the making you feel like your doctor is with you? 0 (0) 2 (1.1) 8 (4.6) 27 (15.5) 137 (78.7)
 A10. How easy was it to disconnect from the telemedicine system? 0 (0) 1 (0.6) 1 (0.6) 15 (8.6) 157 (90.2)
B. Telemedicine health care satisfaction
 B1. Rate how much you were able to tell the doctor about your problems. 0 (0) 0 (0) 1 (0.6) 33 (19) 140 (80.5)
 B2. Rate your satisfaction with the answers you received from the doctor. 0 (0) 0 (0) 1 (0.6) 22 (12.6) 151 (86.8)
 B3. Rate how well the telemedicine system met your health care needs. 0 (0) 0 (0) 16 (9.2) 68 (39.1) 90 (51.7)
 B4. Rate the courtesy, respect, and sincerity of the doctor you consulted. 0 (0) 0 (0) 2 (1.1) 21 (12.1) 151 (86.8)
 B5. Rate the extent to which the doctor respected your privacy and confidentiality. 0 (0) 0 (0) 0 (0) 15 (8.6) 159 (91.4)
 B6. Rate the length of time that the telemedicine system covers until meeting with the doctor. 0 (0) 0 (0) 5 (2.9) 23 (13.2) 146 (83.9)
 B7. Rate how comfortable you felt during the consultation. 0 (0) 0 (0) 2 (1.1) 25 (14.4) 147 (84.5)
 B8. Rate the time savings provided by the telemedicine system. 0 (0) 0 (0) 2 (1.1) 23 (13.2) 149 (85.6)
 B9. Rate the financial savings (travel, accommodation, etc.) provided by the telemedicine system. 0 (0) 0 (0) 4 (2.3) 16 (9.2) 154 (88.5)
 B10. Rate your overall satisfaction with the health care service. 0 (0) 0 (0) 0 (0) 6 (3.4) 168 (96.6)
Overall satisfaction score for telemedicine (technical and health care), mean (SD) 94.6 (±10.1)/100

Discussion

In recent years, telemedicine electronic communication providers have been included within the scope of health service provision as an essential tool, and so the advantages and disadvantages of telemedicine have become a crucial area of study.14 The present study reveals the pros and cons of telemedicine in the clinical follow-up of IMDs. To the best of our knowledge, the present study evaluates the effectiveness of telemedicine in the highest number of IMDs patients to date during the COVID-19 pandemic.

Despite the lack of a telemedicine infrastructure in our country, the parents interviewed within the scope of the research reported a very high level of satisfaction. Almost all participants found it “useful” and stated that they would like to use it in the future. The most common diagnoses in the participants were aminoacidopathies, lipid metabolism disorders, biotinidase deficiency, and lysosomal/peroxisomal diseases, for which follow-up via telemedicine was generally considered appropriate. Around three-quarters of the patients were on oral medication, and half were undergoing diet therapy. The parents stated that the ability to have the doctor following up on medication and diet therapies via telemedicine increased their motivation and reduced unnecessary hospital admissions.

Telemedicine has been shown to be more beneficial in developing countries than developed countries and it contributes to meeting unmet needs and improving health services in countries where the provision of health services is inadequate.15,16 In addition, the diagnosis, treatment, and follow-up of low-income patients with lower costs increase the quality of health services in developing countries.17,18 In the present study, 87.4% of the parents reported an income below the poverty threshold, and 38.1% of those who were not regularly followed up reported that they were unable to attend the outpatient clinic due to financial issues. It can be predicted that telemedicine will become much more helpful for low-income families.

Most doctors specializing in IMDs work in central city hospitals. In a study conducted by the European Reference Network for Hereditary Metabolic Disorders (MetabERN) investigating the social and medical needs of patients with IMDs, 61.1% of the patients said that there was no medical service/doctor specialized in their condition, and 72.3% reported being unable to access specialized emergency services in their region.19 Centers specializing in IMD are predominantly in the metropolises in our country, although 48.8% of our patient population live in rural areas. From this perspective, it is apparent that telemedicine reduces patient referrals, distance traveled, expenses and time, and thus stress.11,12

In the present study, 37.4% of the patients reported living more than 300 km from the hospital, 48.6% said they had traveled for more than an hour, and 27.5% said they had spent more than 50.00 USD. For the 24.7% of the patients in the study advised to attend the hospital for controls at 3-month or shorter intervals, all these financial expenses represent a severe burden for the family. Of the respondents, 67.6% said they had problems finding a place to stay when they came to Ankara, where the hospital is located.

Further, almost one-third spent more than 100.00 USD on accommodation, which constitutes one-third of the monthly income of almost half of the respondents. Financial expenses were not the only reported problem, as 68.4% of the parents said that they needed to take time off work, and 69.6% said that they encountered problems in doing so, which can be considered a severe social barrier. In other studies, telemedicine has been reported to have the significant advantage of reducing the need to take time off from school/work.13,20

The main benefits of telemedicine include ease of access to a doctor and savings in time.10,14,21 Almost all the parents stated that telemedicine had saved them time. When evaluated in terms of the time spent at the hospital, 82.7% of the patients stated that they attended the outpatient clinic more frequently than every 6 months, and 85.6% of the patients reported waiting for their appointment for more than 15 min. Previous studies have reported the advantages of reduced or eliminated waiting times.13,20

Patients reported that in the past they had needed to come to the hospital for laboratory and imaging results, dietitian appointments, prescriptions, and health reports, and the fact that these works can be conducted remotely via telemedicine will contribute significantly to savings of time. Almost all the participants stated that they would like to use telemedicine to learn their test results, whereas 75% said they would like to receive prescriptions/health reports via this route in the future.

Telemedicine also improves the adherence of patients to treatment, while also increasing their motivation and quality of life by increasing their access to medical care.22 Consistently, in our study, half of the parents stated that not coming to regular follow-up appointments is related with low adherence to medications and diet treatment. Being in contact with the health care team in some way will improve patients’ motivation to continue their treatment.

As it is known, access to health care has become problematic during the COVID-19 pandemic. Accordingly, the working days and hours of IMDs centers around the world have been restricted, and some clinics have even closed due to the pandemic.8,23 In a study conducted by the European Organization for Rare Diseases, it is reported that during the pandemic, 70% of patients had postponed their appointments, and 60% had interrupted their treatments.24 In the present study, 45.6% of the patients delayed their controls due to COVID-19 anxiety and lockdown.

Previous studies have reported a deterioration in the results of clinical and laboratory tests of IMDs patients who have disrupted their controls and treatments in the pandemic, as another area in which telemedicine has gained importance.25–27 Telemedicine was already witnessing a rise in popularity even before the pandemic, and its popularity has accelerated as people have become more familiar with technology in a need to reduce their social contacts.5 As this research was also carried out during the pandemic, the general satisfaction may be reported to be high.

Along with the advantages, there are, of course, also disadvantages with telemedicine, with the lack of the ability to undergo a physical examination being among the most common in literature.28 In the present study, the most frequently reported disadvantage was the inability to undergo radiological and laboratory tests, followed by a lack of physical examinations. Regular hospital admissions are required for patients receiving ERT, among whom there were seven in the present study, and almost all of them reported missing their treatment at least once during the COVID-19 pandemic due to the lack of home-infusion therapy in our country.

There are several limitations to the present study. To the best of our knowledge, it is the largest study to date investigating telemedicine in patients with IMDs in terms of the number of respondents, although further studies involving larger groups are needed. The fact that the study was conducted in a single center is also a significant disadvantage. Although the findings reveal the effectiveness of telemedicine only in our country, the present study can serve as a guide for studies in other developing countries.

Conclusions

The COVID-19 pandemic has changed the way we manage health care. As the number of COVID-19 cases continues to rise, patients with IMDs need to be cared for in the safest possible way possible. Our study has shown telemedicine to be a reliable approach to the clinical follow-up of patients with IMDs. The need for this telemedicine is obvious, especially for patients living in rural areas where there is limited or zero access to specialized IMD health care teams. The future of telemedicine in the provision of remote care is promising in IMDs.

Acknowledgments

The authors thank Mustafa Murat and Murat Çoban from the Department of Computer Engineering, Faculty of Engineering, Ankara University, for developing a new video appointment program for the project.

Disclosure Statement

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding Information

No funding was received for this article.

REFERENCES

  • 1. Hollander JE, Carr BG. Virtually perfect? Telemedicine for COVID-19. N Engl J Med 2020;382:1679–1681. Crossref, MedlineGoogle Scholar
  • 2. Chauhan V, Galwankar S, Arquilla B, et al. Novel coronavirus (COVID-19): Leveraging telemedicine to optimize care while minimizing exposures and viral transmission. J Emerg Trauma Shock 2020;13:20–24. MedlineGoogle Scholar
  • 3. Okereafor K, Olajide A, Djehaiche R Exploring the potentials of telemedicine and other non-contact electronic health technologies in controlling the spread of the novel coronavirus disease (COVID-19). Int J IT Eng 2020;8:1–13. Google Scholar
  • 4. Bokolo AJ. Exploring the adoption of telemedicine and virtual software for care of outpatients during and after COVID-19 pandemic. Ir J Med Sci 2021;190:1–10. Crossref, MedlineGoogle Scholar
  • 5. Colbert GB, Venegas-Vera AV, Lerma EV. Utility of telemedicine in the COVID-19 era. Rev Cardiovasc Med 2020;21:583–587. Crossref, MedlineGoogle Scholar
  • 6. Moazzami B, Razavi-Khorasani N, Dooghaie Moghadam A, et al. COVID-19 and telemedicine: Immediate action required for maintaining healthcare providers well-being. J Clin Virol 2020;126:104345. Crossref, MedlineGoogle Scholar
  • 7. Singh RH, Pringle T, Kenneson A. The use of telemedicine and other strategies by registered dietitians for the medical nutrition therapy of patients with inherited metabolic disorders during the COVID-19 pandemic. Front Nutr 2021;8:637868. Crossref, MedlineGoogle Scholar
  • 8. Elmonem MA, Belanger-Quintana A, Bordugo A, et al. The impact of COVID-19 pandemic on the diagnosis and management of inborn errors of metabolism: A global perspective. Mol Genet Metab 2020;131:285–288. Crossref, MedlineGoogle Scholar
  • 9. Morgan DG, Kosteniuk J, Stewart N, et al. The telehealth satisfaction scale: Reliability, validity, and satisfaction with telehealth in a rural memory clinic population. Telemed J E Health 2014;20:997–1003. LinkGoogle Scholar
  • 10. Nguyen M, Waller M, Pandya A, et al. A review of patient and provider satisfaction with telemedicine. Curr Allergy Asthma Rep 2020;20:72. Crossref, MedlineGoogle Scholar
  • 11. Swinfen R, Swinfen P. Low-cost telemedicine in the developing world. J Telemed Telecare 2002;8(Suppl. 3):63–65. Crossref, MedlineGoogle Scholar
  • 12. Vassallo DJ, Hoque F, Roberts MF, et al. An evaluation of the first year’s experience with a low-cost telemedicine link in Bangladesh. J Telemed Telecare 2001;7:125–138. Crossref, MedlineGoogle Scholar
  • 13. Aydemir S, Ocak S, Saygili S, et al. Telemedicine applications in a tertiary pediatric hospital in turkey during COVID-19 pandemic. Telemed J E Health 2021;27:1180–1187. LinkGoogle Scholar
  • 14. Fisk M, Livingstone A, Pit SW. Telehealth in the context of COVID-19: Changing perspectives in Australia, the United Kingdom, and the United States. J Med Internet Res 2020;22:e19264. Crossref, MedlineGoogle Scholar
  • 15. Brandling-Bennett HA, Kedar I, Pallin DJ, et al. Delivering health care in rural Cambodia via store-and-forward telemedicine: A pilot study. Telemed J E Health 2005;11:56–62. LinkGoogle Scholar
  • 16. Pradhan MR. ICTs application for better health in Nepal. Kathmandu Univ Med J (KUMJ) 2004;2:157–163. MedlineGoogle Scholar
  • 17. Mishra A. Telemedice in otolaryngology (An Indian Perspective). Indian J Otolaryngol Head Neck Surg 2003;55:211–212. Crossref, MedlineGoogle Scholar
  • 18. Kifle M, Mbarika VWA, Datta P. Telemedicine in Sub-Saharan Africa: The case of teleophthalmology and eye care in Ethiopia. J Am Soc Inform Sci Technol 2006;57:1383–1393. CrossrefGoogle Scholar
  • 19. Sestini S, Paneghetti L, Lampe C, et al. Social and medical needs of rare metabolic patients: Results from a MetabERN survey. Orphanet J Rare Dis 2021;16:336. Crossref, MedlineGoogle Scholar
  • 20. Utidjian L, Abramson E. Pediatric telehealth: Opportunities and challenges. Pediatr Clin North Am 2016;63:367–378. Crossref, MedlineGoogle Scholar
  • 21. Barnett ML, Ray KN, Souza J, et al. Trends in telemedicine use in a large commercially insured population, 2005–2017. JAMA 2018;320:2147–2149. Crossref, MedlineGoogle Scholar
  • 22. Chanussot-Deprez C, Contreras-Ruiz J. Telemedicine in wound care. Int Wound J 2008;5:651–654. Crossref, MedlineGoogle Scholar
  • 23. Leoni C, Giorgio V, Onesimo R, et al. The dark side of COVID-19: The need of integrated medicine for children with special care needs. Am J Med Genet A 2020;182:1988–1989. Crossref, MedlineGoogle Scholar
  • 24. EURORDIS Rare Diseases Europe. How has COVID-19 impacted people with rare diseases? 2020. Available at https://download2.eurordis.org/rbv/covid19survey/covid_infographics_final.pdf (last accessed October 20, 2021). Google Scholar
  • 25. Yekeduz MK, Kose E, Eminoglu FT. A case with Gaucher disease unable to reach enzyme replacement therapy because of COVID-19 quarantine: The first case from Turkey. Turk Arch Pediatr 2021;56:270–271. Crossref, MedlineGoogle Scholar
  • 26. Kahraman AB, Yildiz Y, Ciki K, et al. Invisible burden of COVID-19: Enzyme replacement therapy disruptions. J Pediatr Endocrinol Metab 2021;34:539–545. Crossref, MedlineGoogle Scholar
  • 27. Andrade-Campos M, Escuder-Azuara B, de Frutos LL, et al. Direct and indirect effects of the SARS-CoV-2 pandemic on Gaucher Disease patients in Spain: Time to reconsider home-based therapies? Blood Cells Mol Dis 2020;85:102478. Crossref, MedlineGoogle Scholar
  • 28. Marcin JP, Ellis J, Mawis R, et al. Using telemedicine to provide pediatric subspecialty care to children with special health care needs in an underserved rural community. Pediatrics 2004;113:1–6. Crossref, MedlineGoogle Scholar





Source link